Ultragenyx Pharmaceutical (RARE) EBIT Growth (3y) (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) EBIT Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ultragenyx Pharmaceutical 2.72 Bn 2.31 Bn 106.00 Mn -3.12%

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.12%
Dec 31, 2025 8.03%
Sep 30, 2025 8.77%
Jun 30, 2025 8.66%
Mar 31, 2025 -1.53%
Dec 31, 2024 -6.04%
Sep 30, 2024 -13.69%
Jun 30, 2024 -12.02%
Mar 31, 2024 -15.77%
Dec 31, 2023 -8.24%
Sep 30, 2023 -42.34%
Jun 30, 2023 -32.88%
Mar 31, 2023 -8.50%
Dec 31, 2022 -15.53%
Sep 30, 2022 -24.00%
Jun 30, 2022 -7.98%
Mar 31, 2022 -11.26%
Dec 31, 2021 -4.32%
Sep 30, 2021 -0.07%
Jun 30, 2021 4.45%